ADC is cleared for clinical development. Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submis ...

But at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), thousands of doctors and researchers rose ...

Innovation City Free Zone strengthens its global footprint through representation in London and Bucharest, creating new ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose ...

Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player. Find out why RVMD ...

Detailed price information for Adlai Nortye Ltd ADR (ANL-Q) from The Globe and Mail including charting and trades.

We recently determined that concurrent inhibition of autophagy, using the lysosomal inhibitor chloroquine (CQ), and of ERK, using a small molecule ERK inhibitor (ERKi), synergistically suppressed the ...

A new research perspective was published in Volume 13 of Oncoscience on June 3, 2026, titled "The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma." ...

First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on prec ...

MADRID and CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, ...